Lerdelimumab

DB06557ExperimentalProtein Based Therapies

Investigated for use/treatment in glaucoma and cataracts.

Mechanism: Pharmacologically active on Transforming growth factor beta-2 proprotein
Curator reviewed
Primary indication: Investigated for use/treatment in glaucoma and cataracts.Curator reviewed
Code names: CAT-152

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lerdelimumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.